Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement with Senior Noteholders on Principal Terms of Plan



K-V Pharmaceutical Secures Commitment for $85 Million Loan, Reaches Agreement
     with Senior Noteholders on Principal Terms of Plan of Reorganization

Financing Will Fund Hologic Settlement Agreement, Provide Additional Financial
Flexibility During Chapter 11 Proceeding and Fund Payments Under
Reorganization Plan

PR Newswire

ST. LOUIS, Dec. 12, 2012

ST. LOUIS, Dec. 12, 2012 /PRNewswire/ -- K-V Pharmaceutical Company ("K-V" or
"the Company") today announced that it has received a commitment from lenders
led by an affiliate of Silver Point Finance LLC for $85 million in senior
secured post-petition debtor-in-possession ("DIP") financing, which the
Company intends to use to, among other things, satisfy the terms of its
recently filed settlement agreement with Hologic, Inc. ("Hologic Settlement"),
provide additional financial flexibility during the pendency of the Company's
Chapter 11 proceeding and fund certain payments under a proposed
reorganization plan.  The new DIP financing, the Hologic Settlement and the
reorganization plan (and related disclosure statement)  are each subject to
approval of the U. S. Bankruptcy Court for the Southern District of New York,
the Honorable Judge Allan L. Gropper presiding.

The Hologic Settlement confirms K-V's continued ownership of Makena® and will
resolve all bankruptcy related disputes between K-V and Hologic, and provides
for mutual releases of all claims between the parties. 

Under the proposed reorganization plan, K-V expects to emerge from Chapter 11
with its entire product portfolio, including Makena®, Clindesse®, Gynazole-1®
and Evamist®.  The Company has provided and is committed to continue to
provide its women's health care products without interruption to meet the
needs of the health care providers and patients it serves.

Prior to the funding of the DIP financing facility, K-V intends to file with
the Bankruptcy Court a proposed reorganization plan, a related disclosure
statement, and a plan support agreement (PSA) with an ad hoc group of senior
secured noteholders.  The principal terms of the proposed reorganization plan
are contained in a plan term sheet filed with the motion to approve the DIP
financing filed with the Bankruptcy Court, which together with other documents
from the Chapter 11 cases, can be found at http://dm.epiq11.com/KVD.

K-V and certain of its affiliates commenced cases to reorganize under Chapter
11 of the U.S. Bankruptcy Code on August 4, 2012. The Chapter 11 cases are
being jointly administered under case number 12-13346.

The DIP Lenders consist of affiliates or funds of each of Silver Point
Finance, LLC, Whitebox Advisors, LLC, and Pioneer Investment Management, Inc.

Willkie Farr & Gallagher LLP serves as bankruptcy counsel to K-V, and
Jefferies & Co., Inc. as financial advisor and investment banker.

Updates and additional information can be found at the Company's website
www.kvph.com. In addition, the Company's Claims Administrator, Epiq Bankruptcy
Solutions, Inc., maintains a web-based resource where documents from the
Chapter 11 cases, including the Company's Petitions, can be found,
http://dm.epiq11.com/KVD.

About K-V Pharmaceutical Company
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with
a primary focus in the area of women's healthcare. As such, we are committed
to advancing the health of women across all the stages of their lives.

For further information about K-V Pharmaceutical Company, please visit the
Company's corporate website at www.kvph.com.

Cautionary Note Regarding Forward-Looking Statements
This release contains various forward-looking statements within the meaning of
the United States Private Securities Litigation Reform Act of 1995 (the
"PSLRA") and which may be based on or include assumptions concerning our
operations, future results and prospects. Such statements may be identified by
the use of words like "plan," "expect," "aim," "believe," "project,"
"anticipate," "commit," "intend," "estimate," "will," "should," "could,"
"potential" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future,
including, without limitation, statements about product launches, governmental
and regulatory actions and proceedings, market position, revenues,
expenditures and the impact of recalls and suspensions of shipments on
revenues, adjustments to the financial statements, the filing of amended
filings with the Securities and Exchange Commission ("SEC") and other
financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are
subject to risk and uncertainties. In connection with the PSLRA's "safe
harbor" provisions, we provide the following cautionary statements identifying
important economic, competitive, political, regulatory and technological
factors, among others, that could cause actual results or events to differ
materially from those set forth or implied by the forward-looking statements
and related assumptions. Such factors include (but are not limited to): (1)
the ability of the Company and its subsidiaries to continue as a going
concern; (2) the risk that the Bankruptcy Court will not approve the Hologic
Settlement; (3) the risk that the Bankruptcy Court will not approve the
Company's entry into the currently proposed DIP financing facility, which is
required to fund the Hologic Settlement ; (4) the ability of the Company and
its subsidiaries to obtain Bankruptcy Court approval with respect to other
motions in the Chapter 11 cases; (5) the ability of the Company and its
subsidiaries to prosecute, develop and consummate one or more plans of
reorganization with respect to the Chapter 11 cases; (6) the effects of the
bankruptcy filing on the Company and its subsidiaries and the interests of
various creditors, equity holders and other constituents; (7) the effects of
rulings of the Bankruptcy Court in the Chapter 11 cases and the outcome of the
cases in general; (8) the length of time the Company and its subsidiaries will
operate under the Chapter 11 cases; (9) risks associated with third-party
motions in the Chapter 11 cases, which may interfere with the ability of the
Company and its subsidiaries to develop one or more plans of reorganization
and consummate such plans once they are developed; (10) the potential adverse
effects of the Chapter 11 proceedings on the Company's liquidity or results of
operations; (11) the ability to execute the Company's business and
restructuring plans; (12) increased legal costs related to the Company's
bankruptcy filing and other litigation; (13) that its Class A Common Stock and
Class B Common Stock will be, or will continue to be, traded on the OTCQB
Marketplace and whether sufficient volumes and liquidity will develop; and
(14) the ability of the Company and its subsidiaries to maintain contracts
that are critical to their operation, including to obtain and maintain normal
terms with their vendors, customers and service providers and to retain key
executives, managers and employees.

This discussion is not exhaustive, but is designed to highlight important
factors that may impact our forward-looking statements.

Because the factors referred to above, as well as the statements included in
Part I, Item 1A—"Risk Factors," of our Annual Report on Form 10-K for the
fiscal year ended March 31, 2012 and under the heading "Risk Factors" in our
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on July 31, 2012, could cause actual results or outcomes to differ
materially from those expressed in any forward-looking statements made by us
or on our behalf, you should not place undue reliance on any forward-looking
statements. All forward-looking statements attributable to us are expressly
qualified in their entirety by the cautionary statements in this "Cautionary
Note Regarding Forward-Looking Statements" and the risk factors that are
included under Part I, Item 1A of our Annual Report on Form 10-K for the
fiscal year ended March 31, 2012 and under the heading "Risk Factors" in our
Registration Statement on Form S-1 filed with the Securities and Exchange
Commission on July 31, 2012. Further, any forward-looking statement speaks
only as of the date on which it is made and we are under no obligation to
update any of the forward-looking statements after the date of this release.
New factors emerge from time to time, and it is not possible for us to predict
which factors will arise, when they will arise and/or their effects. In
addition, we cannot assess the impact of each factor on our future business or
financial condition or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in
any forward-looking statements.

SOURCE K-V Pharmaceutical Company

Website: http://www.kvph.com
Contact: Brainerd Communicators, Inc., Tony Herrling, +1-212-986-6667,
herrling@braincomm.com, or Brad Edwards, +1-212-986-6667,
edwards@braincomm.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement